Evidence map›Paper›PMID 26048639›Full record

ArticleDrug and alcohol dependence2015

Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids.

Nicolaos Christodoulides, Richard De La Garza, Glennon W Simmons, Michael P McRae, Jorge Wong, Thomas F Newton, Regina Smith, James J Mahoney, Justin Hohenstein, Sobeyda Gomez and 8 more

Abstract readControlled Clinical Trial
In one paragraph

Article in Drug and alcohol dependence, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Modified ELISA for Ultrasensitive Diagnosis.Journal of clinical medicine · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Nicolaos ChristodoulidesDepartment of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA.
Richard De La GarzaMenninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA.
Glennon W SimmonsDepartment of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA.
Michael P McRaeDepartment of Bioengineering, Rice University, Houston, TX, USA.
Jorge WongDepartment of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA.
Thomas F NewtonMenninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA; Department of Veterans Affairs Medical Center, Houston, TX, USA.
Regina SmithDepartment of Bioengineering, Rice University, Houston, TX, USA.
James J MahoneyMenninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
Justin HohensteinDepartment of Bioengineering, Rice University, Houston, TX, USA.
Sobeyda GomezDepartment of Bioengineering, Rice University, Houston, TX, USA.
Pierre N FlorianoDepartment of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA.
Humberto TalaveraDepartment of Bioengineering, Rice University, Houston, TX, USA.
Daniel J SloanDepartment of Bioengineering, Rice University, Houston, TX, USA.
David E MoodyCenter for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
David M AndrenyakCenter for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
Thomas R KostenMenninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA; Department of Neuroscience, Baylor College of Medicine, Houston, TX, USA; Department of Veterans Affairs Medical Center, Houston, TX, USA.
Ahmed HaqueDepartment of Bioengineering, Rice University, Houston, TX, USA.
John T McDevittDepartment of Bioengineering, Rice University, Houston, TX, USA; Department of Chemistry, Rice University, Houston, TX, USA; Department Biomaterials, Bioengineering Institute, New York University, 433 First Avenue, Room 820, New York, NY 10010-4086, USA. Electronic address: mcdevitt@nyu.edu.
Rice University · USBaylor College of Medicine · USUniversity of Utah · USNew York University · US

Funding

Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
Effects of Oral Inflammation on the Levels of Salivary Biomarkers of AMIU01DE017793 · NIDCR · UNIVERSITY OF TEXAS AT AUSTIN · PI MCDEVITT, JOHN T · 2006 to 2012
$13.0M
NCATS NIH HHS UL1 TR000371NIDCR NIH HHS 5U01 DE017793NIDCR NIH HHS U01 DE017793
6 · The paper itself

Abstract

objectiveThere is currently a gap in on-site drug of abuse monitoring. Current detection methods involve invasive sampling of blood and urine specimens, or collection of oral fluid, followed by qualitative screening tests using immunochromatographic cartridges. While remote laboratories then may provide confirmation and quantitative assessment of a presumptive positive, this instrumentation is expensive and decoupled from the initial sampling making the current drug-screening program inefficient and costly. The authors applied a noninvasive oral fluid sampling approach integrated with the in-development chip-based Programmable bio-nano-chip (p-BNC) platform for the detection of drugs of abuse.

methodThe p-BNC assay methodology was applied for the detection of tetrahydrocannabinol, morphine, amphetamine, methamphetamine, cocaine, methadone and benzodiazepines, initially using spiked buffered samples and, ultimately, using oral fluid specimen collected from consented volunteers.

resultsRapid (∼10min), sensitive detection (∼ng/mL) and quantitation of 12 drugs of abuse was demonstrated on the p-BNC platform. Furthermore, the system provided visibility to time-course of select drug and metabolite profiles in oral fluids; for the drug cocaine, three regions of slope were observed that, when combined with concentration measurements from this and prior impairment studies, information about cocaine-induced impairment may be revealed.

conclusionsThis chip-based p-BNC detection modality has significant potential to be used in the future by law enforcement officers for roadside drug testing and to serve a variety of other settings, including outpatient and inpatient drug rehabilitation centers, emergency rooms, prisons, schools, and in the workplace.

Indexed as

Lab-On-A-Chip DevicesHumansIllicit DrugsSalivaSingle-Blind MethodSubstance Abuse DetectionIllicit DrugsDrugs of abuseMultiplexedOn-site testingOral fluidProgrammable bio-nano-chip

Identifiers

PMID26048639
PMCPMC4509839
OpenAlexW1856624661

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.